Hematological Ex Vivo Assays

Champions Oncology also offers a series of hematological ex vivo assays for testing leukemias, including acute myeloid leukemia (AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), and Mantle Cell Lymphoma (MCL).  In each assay that was custom developed for each leukemic indication, blood was collected from patients and then plated in culture ex vivo with both therapeutic candidates as well as standards of care. Endpoints available for these studies are: 

  • Cell Proliferation
  • Tumor Cytotoxicity
  • Apoptosis
  • Phenotyping by Flow Cytometry
  • Gene Expression

Testing your therapeutic candidates in an ex vivo platform prior to a PDX model can be a cost-effective way for screening your top targets.